These include nausea, vomiting, diarrhea, stomach pain, and constipation
Today, adjunctive therapies for type 1 diabetes that are not yet FDA approved include the glucose-lowering GLP-1s and SGLT-2s
Serena Williams turns to GLP-1 drugs: Is it a new era in weight loss
People who developed NAION after taking Rybelsus can talk to an attorney about eligibility for filing a case
The published human data supporting BPC-157 may not be strong, but, he argued, forbidding American companies from providing it would move it deeper into a market with no production or sourcing standards, no physician, no monitoring, and no record. That view was echoed by Jeffrey Egler, the chief medical officer at the telehealth company Noom